World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://www.wjon.org

Case Report

Volume 15, Number 5, October 2024, pages 837-843

An Extremely Rare Case of Primary Malignant Melanoma of the Kidney

Figures

Figure 1.
Figure 1. Computed tomography scan revealed a tumor (arrows) in the lower pole of the right kidney: (a) axial and (b) coronal view.
Figure 2.
Figure 2. Grossly, the cut surface of the tumor (7 cm in diameter), surrounded by a dashed line, was dark brown in color. The distance between the tumor and the renal pelvis is 1 cm (scale bar (black): 10 mm).
Figure 3.
Figure 3. (a) Histologically, a tumor was demarcated by the thick fibrous capsule (double-headed arrow) (hematoxylin and eosin stain, scale bar: 200 µm, original magnification: × 40). (b) The tumor cells with large nucleoli and abundant melanin granules in acidophilic cytoplasm showed papillary, solid, and/or alveolar growth patterns (hematoxylin and eosin stain, scale bar: 20 µm, original magnification: × 400). MM: malignant melanoma; Nl: normal renal tissue.
Figure 4.
Figure 4. Immunohistochemical examination indicated positivity for (a) Melan A, (b) HMB45, and (c) S-100 in the tumor cells (scale bar: 20 µm, original magnifications: × 400). HMB45: human melanoma black 45; S-100: soluble 100 protein.
Figure 5.
Figure 5. Immunohistochemistry indicated negativity of tumor cells for (a) TFE3, (b) TFEB, (c) CK7, and (d) CA9 (scale bar: 20 µm, original magnifications: × 400). TFE3: transcription factor E3; TFEB: transcription factor EB; CK7: cytokeratin 7; CA9: carbonic anhydrase 9.

Table

Table 1. Cases of Primary Malignant Melanoma in the Kidney
 
Authors, yearTumor size (cm)Age, years/sexTreatmentFollow-up
aMalignant melanoma developed in the renal pelvis. TRK: total resection of kidney; PRK: partial resection of kidney; LY: lymphadenectomy; CHT: chemotherapy; AI: adjuvant immunotherapy.
Frasier et al, 1988 [15]a5 × 4 × 337/maleTRK and AI22 months
Fujimoto et al, 1995 [14]2.5 × 254/femalePRK and CHT44 months
Tajima et al, 1997 [16]3 - 3.574/femaleTRK2 years and 3 months
Bayazit et al, 2002 [17]7 - 837/maleTRK and LY1 year
Tasdemir et al, 2011 [18]4.567/maleTRK2 weeks (the patient refused CHT)
Liapis et al, 2016 [19]a2.5 × 2.2 × 235/maleCHT6 months
Present case745/femaleTRK18 months